Urological Malignancies Clinical Trial
— GS-PET-2008Official title:
A Comparative Study to Examine the Accuracy of CHOLINE PET CT in the Diagnosis
| NCT number | NCT00706212 |
| Other study ID # | GS-PET-2008 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | June 26, 2008 |
| Last updated | June 26, 2008 |
| Start date | June 2008 |
PET CT is one of the imaging tools that are used for staging of urological malignancies.
C11 Choline is a novel isotope with the advantage of its minimal secretion in the urine.
This advantage makes it a potentially better metabolic marker then others such as FDG.
Preliminary studies showed ~95% sensitivity in the diagnosis of TCC. Our Goal is to continue
the evaluation of this method as a diagnostic and follow up tool in different urological
malignancies.
| Status | Recruiting |
| Enrollment | 60 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients older then 18 years of age - Full consciousness and awareness - suspected to suffer from urological malignancy and a candidate for a surgical procedur Exclusion Criteria: - known secondary malignancy |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Israel | Rabin Medical Center, Beilinson hospital | Petach Tikva |
| Lead Sponsor | Collaborator |
|---|---|
| Rabin Medical Center |
Israel,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04625556 -
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
|